- Home
- MARA vs APLS Comparison
MARA vs APLS Comparison
Compare MARA & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MARA
- APLS
- Stock Information
- Founded
- MARA 2010
- APLS 2009
- Country
- MARA United States
- APLS United States
- Employees
- MARA N/A
- APLS N/A
- Industry
- MARA EDP Services
- APLS Biotechnology: Pharmaceutical Preparations
- Sector
- MARA Technology
- APLS Health Care
- Exchange
- MARA Nasdaq
- APLS Nasdaq
- Market Cap
- MARA 5.1B
- APLS 4.4B
- IPO Year
- MARA N/A
- APLS 2017
- Fundamental
- Price
- MARA $24.18
- APLS $27.75
- Analyst Decision
- MARA Buy
- APLS Buy
- Analyst Count
- MARA 8
- APLS 19
- Target Price
- MARA $22.57
- APLS $49.89
- AVG Volume (30 Days)
- MARA 70.4M
- APLS 4.0M
- Earning Date
- MARA 11-12-2024
- APLS 11-05-2024
- Dividend Yield
- MARA N/A
- APLS N/A
- EPS Growth
- MARA N/A
- APLS N/A
- EPS
- MARA 0.62
- APLS N/A
- Revenue
- MARA $598,752,000.00
- APLS $715,216,000.00
- Revenue This Year
- MARA $75.94
- APLS $95.59
- Revenue Next Year
- MARA $36.98
- APLS $13.77
- P/E Ratio
- MARA $38.97
- APLS N/A
- Revenue Growth
- MARA 131.04
- APLS 162.10
- 52 Week Low
- MARA $10.76
- APLS $24.34
- 52 Week High
- MARA $34.09
- APLS $73.80
- Technical
- Relative Strength Index (RSI)
- MARA 62.33
- APLS 47.09
- Support Level
- MARA $17.72
- APLS $25.76
- Resistance Level
- MARA $26.19
- APLS $30.80
- Average True Range (ATR)
- MARA 2.27
- APLS 1.84
- MACD
- MARA 0.23
- APLS 0.04
- Stochastic Oscillator
- MARA 81.53
- APLS 52.79
About MARA Marathon Digital Holdings Inc.
Marathon Digital Holdings Inc focuses on mining digital assets. It owns crypto-currency mining machines and a data center to mine digital assets. The company currently operates in the Digital Currency Blockchain segment. The Crypto-currency Machines are located in the United States.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.